Abstract

Summary

This critical review evaluates the emerging evidence for blue light blocking (450–470 nm wavelength) as a therapeutic intervention in bipolar disorder, finding preliminary but limited clinical support. It highlights the neurobiological pathways involved—particularly melanopsin-driven circadian disruption—and calls for standardized research criteria to guide both future studies and clinical practice.
Abstract

Key Findings

  • Evidence base is limited to a small number of clinical studies, with findings considered preliminary rather than conclusive.
  • Blue light blocking targeting 450–470 nm wavelengths is proposed to modulate circadian-related neurobiological pathways potentially involved in bipolar mood episodes.
  • The review identifies a need for standardized research criteria (e.g., dosing, timing, patient selection) before blue light blocking can be recommended as a routine clinical treatment for bipolar disorder.
Categories

Categories

Mood & Mental Wellness: Reviews evidence for blue light blocking as a treatment modality for bipolar disorder, particularly manic episodes.
Sleep & Circadian Health: Examines the circadian and melanopsin-mediated neurobiology underlying blue light's role in mood regulation and bipolar symptom cycling.
The Science of Light: Discusses the photobiological mechanisms of short-wavelength (450–470 nm) light blocking and its implications for psychiatric treatment protocols.
Authors

Author(s)

I Mylona, GD Floros
Publication Date

Publication Year

2022
Citations

Number of Citations

2
View more publications